Transapical transcatheter aortic valve replacement in bicuspid aortic valve patients: In-hospital outcomes
- VernacularTitle:二叶式主动脉瓣疾病患者经心尖经导管主动脉瓣置换术后院内结局分析
- Author:
Xuan HUANG
1
,
2
;
Lulu LIU
3
;
Tingxi ZHU
1
,
2
;
Kehan LI
4
;
Yingqiang GUO
3
;
Xiaoyan YANG
1
,
2
Author Information
1. 1. West China Biomedical Big Data Center, West China Hospital/West China School of Medicine, Sichuan University, Chengdu, 610041, P. R. China
2. 2. Med-X Center for Informatics, Sichuan University, Chengdu, 610041, P. R. China
3. Department of Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu, 610041, P. R. China
4. West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, 610041, P. R. China
- Publication Type:Journal Article
- Keywords:
Transapical transcatheter aortic valve replacement;
bicuspid aortic valve;
transapical approach;
J-ValveTM;
aortic valve disease
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2023;30(08):1128-1136
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the in-hospital outcomes of transapical transcatheter aortic valve replacement (TA-TAVR) for bicuspid aortic valve (BAV) patients and tricuspid aortic valve (TAV) patients. Methods Patients (including BAV and TAV patients) who underwent TA-TAVR with the J-ValveTM in West China Hospital from July 2014 to July 2020 were included consecutively. The clinical outcomes of the patients were analyzed. Results A total of 354 patients were included in the study, 75 in the BAV group and 279 in the TAV group. There were 229 males and 125 females with a mean age of 72.2±6.0 years. No death occurred during the procedure, and the overall technical success rate was 97.7%. The all-cause in-hospital mortality rate was 1.4%. Twenty (26.7%) patients with BAV and 46 (16.5%) patients with TAV had mild or higher perivalvular leaks immediately after the procedure. No patients with BAV required permanent pacemaker implantation postoperatively, while 13 (4.7%) TAV patients required permanent pacemaker implantation, with an overall pacemaker implantation rate of 3.7%. One (1.3%) BAV patient and 7 (2.5%) TAV patients developed acute kidney injury postoperatively. One (1.3%) BAV patient and 1 (0.4%) TAV patient developed peri-operative myocardial infarction. The average postoperative hospital stay was 7.6±3.6 d for BAV patients and 8.6±6.1 d for TAV patients. There was no statistical difference in primary or secondary in-hospital outcomes between BAV and TAV patients (P>0.05). Conclusion Compared to TAV patients, BAV patients have similar in-hospital outcomes, with a low incidence of adverse clinical outcomes, which provides preliminary evidence for its implementation in Chinese patients with a high proportion of BAV.
